<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03350256</url>
  </required_header>
  <id_info>
    <org_study_id>SJM-CIP-10215</org_study_id>
    <nct_id>NCT03350256</nct_id>
  </id_info>
  <brief_title>BurstDR™ micrOdosing stimuLation in De-novo Patients</brief_title>
  <acronym>BOLD</acronym>
  <official_title>BurstDR™ micrOdosing stimuLation in De-novo Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the therapeutic efficacy of microdosing BurstDR
      stimulation in spinal cord stimulation (SCS) patients with chronic intractable back and/or
      leg pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Microdosing BurstDR consists of periods during which stimulation is delivered with standard
      BurstDR stimulation parameters alternated with periods during which no stimulation is being
      delivered.

      In this study the investigators propose to evaluate therapeutic efficacy of BurstDR
      microdosing, and determine optimal microdosing programming parameters in chronic pain
      patients, who are eligible for SCS therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Actual">July 2, 2019</completion_date>
  <primary_completion_date type="Actual">July 2, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Analog Scale Pain (VAS) Scores Between Baseline and Trial Stimulation</measure>
    <time_frame>baseline and 1 week after trial lead implant (trial stimulation)</time_frame>
    <description>Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 1</measure>
    <time_frame>Baseline and 1 month follow up visit</time_frame>
    <description>Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 2</measure>
    <time_frame>Baseline and 3 month follow up visit</time_frame>
    <description>Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 3</measure>
    <time_frame>Baseline and 6 month follow up visit</time_frame>
    <description>Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Between Baseline and Trial Stimulation</measure>
    <time_frame>Baseline and 1 week after trial lead implant (trial stimulation)</time_frame>
    <description>Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Between Baseline and Follow up 1</measure>
    <time_frame>Baseline and 1 month follow up visit</time_frame>
    <description>Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Between Baseline and Follow up 2</measure>
    <time_frame>Baseline and 3 month follow up visit</time_frame>
    <description>Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Between Baseline and Follow up 3</measure>
    <time_frame>Baseline and 6 month follow up visit</time_frame>
    <description>Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disability Index Between Baseline and Trial Stimulation</measure>
    <time_frame>Baseline and 1 week after trial lead implant (trial stimulation)</time_frame>
    <description>questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disability Index Between Baseline and and Follow up 1</measure>
    <time_frame>Baseline and 1 month follow up visit</time_frame>
    <description>questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disability Index Between Baseline and and Follow up 2</measure>
    <time_frame>Baseline and 3 month follow up visit</time_frame>
    <description>questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disability Index Between Baseline and and Follow up 3</measure>
    <time_frame>Baseline and 6 month follow up visit</time_frame>
    <description>questionnaire on disability (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Catastrophizing Scale Between Baseline and Trial Stimulation</measure>
    <time_frame>Baseline and 1 week after trial lead implant (trial stimulation)</time_frame>
    <description>Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Catastrophizing Scale Between Baseline and Follow up 1</measure>
    <time_frame>Baseline and 1 month follow up visit</time_frame>
    <description>Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Catastrophizing Scale Between Baseline and Follow up 2</measure>
    <time_frame>Baseline and 3 month follow up visit</time_frame>
    <description>Questionnaire on pain catastrophizing (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Catastrophizing Scale Between Baseline and Follow up 3</measure>
    <time_frame>Baseline and 6 month follow up visit</time_frame>
    <description>Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Stimulation ON/OFF Ratio</measure>
    <time_frame>6 month follow up visit</time_frame>
    <description>Percentage of patients using each ON/OFF ratio</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pain, Intractable</condition>
  <condition>Pain, Back</condition>
  <arm_group>
    <arm_group_label>Microdosing group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.</intervention_name>
    <description>BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
    <arm_group_label>Microdosing group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able to provide informed consent to participate in the study;

          -  Subject diagnosed with chronic intractable pain associated with back and/or limbs;

          -  Subject is 18 years of age or older;

          -  Subject has failed to respond to at least 6 months of conventional treatment which may
             include pharmacological treatment, physical therapy, epidural injections;

          -  Subject has a back and/or leg pain intensity of at least 6.0 cm out of 10.0 cm on the
             average back and/or leg pain visual analogue scale at baseline;

          -  Subject's medical record has been evaluated by the Investigator to ensure that the
             subject is a good candidate for a neurostimulation system;

          -  Subject is on stable pain medications with a total opioid for at least 28 days prior
             to enrolling in this study, and is willing to stay on those medications with no dose
             increase until the 3 month visit;

          -  Subject is willing to cooperate with the study requirements including compliance with
             the regimen and completion of all office visits;

          -  Female candidates of child-bearing potential agree to commit to the use of an
             effective method of contraception (including but not limited to sterilization, barrier
             devices, oral contraceptives, intrauterine devices (IUDs), condoms, rhythm method, or
             abstinence) for the duration of the study

        Exclusion Criteria:

        Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive
        peripheral vascular disease, post-herpetic neuralgia or uncontrolled diabetes mellitus;

          -  Subject is currently participating in a clinical investigation that includes an active
             treatment arm;

          -  Subject has been implanted with or participated in a trial period for a
             neurostimulation system;

          -  Subject has an infusion pump;

          -  Subject has evidence of an active disruptive psychological or psychiatric disorder as
             determined as per standard of care;

          -  Subject has a current diagnosis of a progressive neurological disease as determined by
             the Investigator;

          -  Subject is immunocompromised;

          -  Subject has an existing medical condition that is likely to require repetitive MRI
             evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma,
             tumor);

          -  Subject has history of cancer requiring active treatment in the last 12 months;

          -  Subject has an existing medical condition that is likely to require the use of
             diathermy in the future;

          -  Subject has documented history of allergic response to titanium or silicone;

          -  Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or
             substance dependency in the 6 months prior to baseline data collection;

          -  Subject is a female candidates of child bearing potential that are pregnant (confirmed
             by positive urine/blood pregnancy test);

          -  Subject has life expectancy of less than 6 months;

          -  Subject is involved in an injury claim under current litigation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy R Deer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Center for Pain Relief</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thrive Clinic</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada advanced pain specialists</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambulatory Surgery Center of Killeen</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <zip>76542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Pain Solutions</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <results_first_submitted>February 24, 2020</results_first_submitted>
  <results_first_submitted_qc>February 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2020</results_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Intractable</mesh_term>
    <mesh_term>Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03350256/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Microdosing Group</title>
          <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Spinal Cord Stimulation Trial</title>
              <participants_list>
                <participants group_id="P1" count="50">Subject that underwent SCS trial</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Permanent Implant</title>
              <participants_list>
                <participants group_id="P1" count="35">subjects that underwent permanent SCS implant</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>1 Month Follow up</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 Month Follow up</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Month Follow up</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inclusion/exclusion violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Recommended for other therapies</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Denial by insurance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial failure</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not proceed to permanent implant</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject moving out of state</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Included subjects that started the SCS trial (50). One subjects had missing demographic data</population>
      <group_list>
        <group group_id="B1">
          <title>Microdosing Group</title>
          <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>duration of pain</title>
          <population>One subject had missing data for duration of pain</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.98" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Analog Scale Pain (VAS) Scores Between Baseline and Trial Stimulation</title>
        <description>Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)</description>
        <time_frame>baseline and 1 week after trial lead implant (trial stimulation)</time_frame>
        <population>Change in visual analogue scale score between baseline and spinal cord stimulation (SCS) trial missing data for 3 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analog Scale Pain (VAS) Scores Between Baseline and Trial Stimulation</title>
          <description>Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)</description>
          <population>Change in visual analogue scale score between baseline and spinal cord stimulation (SCS) trial missing data for 3 subjects</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.28" spread="23.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 1</title>
        <description>Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)</description>
        <time_frame>Baseline and 1 month follow up visit</time_frame>
        <population>Change in VAS score between baseline and 1 month follow up missing data for 2 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 1</title>
          <description>Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)</description>
          <population>Change in VAS score between baseline and 1 month follow up missing data for 2 subjects</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.07" spread="24.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 2</title>
        <description>Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)</description>
        <time_frame>Baseline and 3 month follow up visit</time_frame>
        <population>Change in VAS between baseline and 3 month follow up missing data for 2 subject</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 2</title>
          <description>Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)</description>
          <population>Change in VAS between baseline and 3 month follow up missing data for 2 subject</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.56" spread="29.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 3</title>
        <description>Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)</description>
        <time_frame>Baseline and 6 month follow up visit</time_frame>
        <population>Change in VAS score between baseline and 6 months visit</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analog Scale Pain Scores Between Baseline and Follow up 3</title>
          <description>Pain questionnaire - (Scale is 0-100 mm with 0 meaning no pain and 100 meaning worst pain imaginable)</description>
          <population>Change in VAS score between baseline and 6 months visit</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.62" spread="29.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life Between Baseline and Trial Stimulation</title>
        <description>Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)</description>
        <time_frame>Baseline and 1 week after trial lead implant (trial stimulation)</time_frame>
        <population>Change in EQ-5D score between baseline and SCS trial
1 subject had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life Between Baseline and Trial Stimulation</title>
          <description>Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)</description>
          <population>Change in EQ-5D score between baseline and SCS trial
1 subject had missing data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.172" spread="0.1625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life Between Baseline and Follow up 1</title>
        <description>Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)</description>
        <time_frame>Baseline and 1 month follow up visit</time_frame>
        <population>Change in EQ-5D score between baseline and 1 month follow up Two subjects had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life Between Baseline and Follow up 1</title>
          <description>Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)</description>
          <population>Change in EQ-5D score between baseline and 1 month follow up Two subjects had missing data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.148" spread="0.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life Between Baseline and Follow up 2</title>
        <description>Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)</description>
        <time_frame>Baseline and 3 month follow up visit</time_frame>
        <population>Change in EQ-5D score between baseline and 3 month follow up One subjects had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life Between Baseline and Follow up 2</title>
          <description>Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)</description>
          <population>Change in EQ-5D score between baseline and 3 month follow up One subjects had missing data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.106" spread="0.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life Between Baseline and Follow up 3</title>
        <description>Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)</description>
        <time_frame>Baseline and 6 month follow up visit</time_frame>
        <population>Change in EQ-5D score between baseline and 6 month follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life Between Baseline and Follow up 3</title>
          <description>Questionnaire on quality of life using european quality of life - 5 dimension questionnaire (EQ-5D) - (Scale is between 0 and 1 with 0 being worse quality of life and 1 best quality of life)</description>
          <population>Change in EQ-5D score between baseline and 6 month follow up</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.148" spread="0.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Disability Index Between Baseline and Trial Stimulation</title>
        <description>questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)</description>
        <time_frame>Baseline and 1 week after trial lead implant (trial stimulation)</time_frame>
        <population>Change in ODI score between baseline and SCS trial 3 subjects had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Disability Index Between Baseline and Trial Stimulation</title>
          <description>questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)</description>
          <population>Change in ODI score between baseline and SCS trial 3 subjects had missing data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.6" spread="18.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Disability Index Between Baseline and and Follow up 1</title>
        <description>questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)</description>
        <time_frame>Baseline and 1 month follow up visit</time_frame>
        <population>Change in ODI score between baseline and 1 month follow up 2 subjects had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Disability Index Between Baseline and and Follow up 1</title>
          <description>questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)</description>
          <population>Change in ODI score between baseline and 1 month follow up 2 subjects had missing data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.76" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Disability Index Between Baseline and and Follow up 2</title>
        <description>questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)</description>
        <time_frame>Baseline and 3 month follow up visit</time_frame>
        <population>Change in disability score between baseline and 3 month follow up Two subjects had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Disability Index Between Baseline and and Follow up 2</title>
          <description>questionnaire on disability, Oswestry Disability Index (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)</description>
          <population>Change in disability score between baseline and 3 month follow up Two subjects had missing data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Disability Index Between Baseline and and Follow up 3</title>
        <description>questionnaire on disability (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)</description>
        <time_frame>Baseline and 6 month follow up visit</time_frame>
        <population>Change in disability score between baseline and 6 month follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Disability Index Between Baseline and and Follow up 3</title>
          <description>questionnaire on disability (ODI) - (Scale is between 0 and 100 with 0 being no disability and 100 worst disability)</description>
          <population>Change in disability score between baseline and 6 month follow up</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.5" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Catastrophizing Scale Between Baseline and Trial Stimulation</title>
        <description>Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)</description>
        <time_frame>Baseline and 1 week after trial lead implant (trial stimulation)</time_frame>
        <population>Change in PCS between baseline and SCS trial One subject had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Catastrophizing Scale Between Baseline and Trial Stimulation</title>
          <description>Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)</description>
          <population>Change in PCS between baseline and SCS trial One subject had missing data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.98" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Catastrophizing Scale Between Baseline and Follow up 1</title>
        <description>Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)</description>
        <time_frame>Baseline and 1 month follow up visit</time_frame>
        <population>Change in PCS score between baseline and 1 month follow up 2 subjects had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Catastrophizing Scale Between Baseline and Follow up 1</title>
          <description>Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)</description>
          <population>Change in PCS score between baseline and 1 month follow up 2 subjects had missing data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.17" spread="12.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Catastrophizing Scale Between Baseline and Follow up 2</title>
        <description>Questionnaire on pain catastrophizing (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)</description>
        <time_frame>Baseline and 3 month follow up visit</time_frame>
        <population>Change in PCS between baseline and 3 month follow up 2 subjects had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Catastrophizing Scale Between Baseline and Follow up 2</title>
          <description>Questionnaire on pain catastrophizing (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)</description>
          <population>Change in PCS between baseline and 3 month follow up 2 subjects had missing data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.32" spread="14.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Catastrophizing Scale Between Baseline and Follow up 3</title>
        <description>Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)</description>
        <time_frame>Baseline and 6 month follow up visit</time_frame>
        <population>Change in PCS score between baseline and 6 month follow up
1 subject had missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Catastrophizing Scale Between Baseline and Follow up 3</title>
          <description>Questionnaire on pain catastrophizing, Pain Catastrophising Scale (PCS) - (Scale is between 0 and 52 with 0 being no catastrophising and 52 worst catastrophising)</description>
          <population>Change in PCS score between baseline and 6 month follow up
1 subject had missing data</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.42" spread="12.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Stimulation ON/OFF Ratio</title>
        <description>Percentage of patients using each ON/OFF ratio</description>
        <time_frame>6 month follow up visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Microdosing Group</title>
            <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
          </group>
        </group_list>
        <measure>
          <title>Stimulation ON/OFF Ratio</title>
          <description>Percentage of patients using each ON/OFF ratio</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>subjects using 360 seconds OFF intervals</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>subjects using 240 seconds OFF intervals</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>subjects using 150 seconds OFF intervals</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>subjects using 120 seconds OFF intervals</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>subjects using 90 seconds OFF intervals</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment to completion of the study at 6 month follow up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Microdosing Group</title>
          <description>Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subject fractured &lt;1 vertebrae (compression) and was hospitalized overnight</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trial lead migration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Filippo Agnesi</name_or_title>
      <organization>Abbott</organization>
      <phone>+19725264860</phone>
      <email>filippo.agnesi@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

